PI3K

Phosphoinositide 3-kinases (PI3Ks) are lipid kinases that catalyze the phosphorylation of phosphatidylinositol 4,5-bisphosphate (PI(4,5)P₂) to generate the second messenger phosphatidylinositol (3,4,5)-trisphosphate (PI(3,4,5)P₃). The production of PI(3,4,5)P₃ facilitates the recruitment and activation of pleckstrin homology (PH) domain–containing proteins at the plasma membrane, thereby initiating downstream signaling cascades essential for cellular proliferation, survival, and migration.

PI3Ks are divided into three major classes, among which Class I PI3Ks are most prominently implicated in cancer biology. Class I enzymes comprise four distinct catalytic isoforms: PI3Kα, PI3Kβ, PI3Kδ, and PI3Kγ.

Class IA PI3Ks, the subclass most commonly associated with oncogenic signaling, function as heterodimeric lipid kinases composed of a catalytic p110 subunit (p110α, p110β, or p110δ, encoded by PIK3CA, PIK3CB, and PIK3CD, respectively) and a regulatory p85 subunit.

The PI3K signaling pathway plays a central role in diverse biological processes, including cell cycle progression, cellular growth, survival, actin cytoskeletal rearrangement, migration, and intracellular vesicular trafficking.

Frequently Asked Questions
Phosphoinositide 3-kinases (PI3Ks) are a family of lipid kinases that phosphorylate phosphatidylinositol lipids to regulate cell growth, survival, metabolism, and immune signaling. PI3K activation leads to downstream AKT and mTOR pathway signaling. Aberrant PI3K signaling is frequently observed in cancer due to PIK3CA mutations, PTEN loss, or receptor tyrosine kinase activation.
Class I PI3Ks include four catalytic isoforms: PI3Kα (PIK3CA) PI3Kβ (PIK3CB) PI3Kδ (PIK3CD) PI3Kγ (PIK3CG) PI3Kα and β are broadly expressed, while PI3Kδ and γ are enriched in leukocytes and play critical roles in immune regulation. Isoform selectivity is an important consideration in drug development due to toxicity and immune effects.
PI3K inhibitors can be classified as: Pan-PI3K inhibitors Isoform-selective inhibitors (α, β, δ, γ) Dual PI3K/mTOR inhibitors Irreversible inhibitors Selectivity influences therapeutic window and toxicity profile.
While PI3K inhibitors block upstream lipid kinase activity, mTOR inhibitors act downstream at the level of mTORC1 or mTORC2. Dual PI3K/mTOR inhibitors target both nodes of the pathway and may achieve broader pathway suppression.

Items 276-300 of 369

  • PQR514
    Cat. No.
    A79799

    PQR514

    PQR514 is a potent inhibitor of phosphoinositide 3-kinase (PI3K), demonstrating significant anticancer activity. This compound effectively inhibits cancer cell proliferation and exhibits substantial antitumor effects in the OVCAR-3 xenograft model, with required concentrations notably lower than those of other PI3K inhibitors. PQR514 features favorable pharmacokinetic properties and minimal brain penetration, positioning it as an optimized candidate for targeting systemic tumors in cancer research applications.

    1 mg
    $265.00
    5 mg
    $650.00
    All 5 sizes
  • (S)-PI3Kα-IN-4
    Cat. No.
    A79800

    (S)-PI3Kα-IN-4

    (S)-PI3Kα-IN-4 is a highly selective inhibitor of the phosphoinositide 3-kinase alpha (PI3Kα) isoform, demonstrating an IC50 value of 2.3 nM. This compound exhibits significant selectivity, with 38.3-fold preference for PI3Kα over PI3Kβ, and more than 4-fold selectivity compared to PI3Kδ and PI3Kγ. (S)-PI3Kα-IN-4 is suitable for research applications focusing on cancer biology, particularly in studies aimed at understanding the role of PI3Kα in tumorigenesis and therapeutic resistance.

    5 mg
    $230.00
    10 mg
    $385.00
    All 5 sizes
  • Vulolisib
    Cat. No.
    A79801

    Vulolisib

    Vulolisib is a potent, orally active inhibitor of phosphatidylinositol 3-kinase (PI3K), demonstrating IC50 values of 0.2 nM for PI3Kα, 168 nM for PI3Kβ, 90 nM for PI3Kγ, and 49 nM for PI3Kδ. This compound exhibits significant antiproliferative and antineoplastic properties, making it a valuable tool for cancer research. Its selective inhibition of PI3K isoforms facilitates investigations into the role of PI3K signaling in various malignancies.

    5 mg
    $640.00
    10 mg
    $1,050.00
    All 5 sizes
  • PI3Kδ/γ-IN-1
    Cat. No.
    A79802

    PI3Kδ/γ-IN-1

    PI3Kδ/γ-IN-1 is a selective inhibitor targeting phosphoinositide 3-kinase delta (PI3Kδ) and gamma (PI3Kγ), demonstrating high potency in inhibiting their activity. This compound plays a pivotal role in the study of hematological malignancies, facilitating research into the underlying molecular mechanisms and potential therapeutic approaches for conditions such as leukemia and lymphoma. Its specificity for PI3Kδ and PI3Kγ makes it an invaluable tool for investigating the contributions of these isoforms in cancer biology.

    5 mg
    $260.00
    10 mg
    $435.00
    All 5 sizes
  • NVS-PI3-4
    Cat. No.
    A79803

    NVS-PI3-4

    NVS-PI3-4 is a selective inhibitor of PI3Kγ, playing a crucial role in modulating the PI3K signaling pathway. This compound demonstrates significant inhibitory activity, making it a valuable tool for investigating the mechanisms underlying allergies, inflammatory disorders, and various cancer types. Researchers can utilize NVS-PI3-4 to explore therapeutic strategies aimed at targeting PI3Kγ-related pathways in relevant disease models.

    5 mg
    $125.00
    10 mg
    $200.00
    All 5 sizes
  • Benzoin
    Cat. No.
    A79804

    Benzoin

    Synonyms: DL-Benzoin; Desyl alcohol; (±)-2-Hydroxy-2-phenylacetophenone

    Benzoin is a potent inhibitor of the phosphoinositide 3-kinase alpha (PI3Kα) signaling pathway, known for its potential anticancer effects. This compound has been shown to effectively impede the growth of the colon cancer cell line HCT-116, making it a valuable tool for cancer research. Its application in studying PI3Kα-mediated processes provides insights into therapeutic strategies for colon malignancies.

    1 g
    $20.00
    100 g
    $25.00
    All 4 sizes
  • AS-041164
    Cat. No.
    A79805

    AS-041164

    AS-041164 is a selective inhibitor of the PI3Kγ isoform, demonstrating a potent inhibitory effect with an IC50 of 70 nM. This compound exhibits significantly reduced activity against other isoforms, including PI3Kα, PI3Kβ, and PI3Kδ, with IC50 values of 240 nM, 1.45 μM, and 1.70 μM, respectively. AS-041164 is recognized for its anti-inflammatory properties and is applicable in research focused on inflammation-related pathways and diseases.

    5 mg
    $40.00
    10 mg
    $45.00
    All 5 sizes
  • MIPS-9922
    Cat. No.
    A79806

    MIPS-9922

    MIPS-9922 is a potent and selective inhibitor of PI3Kβ, exhibiting an IC50 of 63 nM. This compound demonstrates over 30-fold higher potency for PI3Kβ compared to PI3Kδ. MIPS-9922 effectively disrupts PI3K-mediated activation of platelet glycoprotein αIIbβ3 and platelet adhesion in vitro, making it a valuable tool for studying anti-platelet and anti-thrombotic activities in research applications.

    5 mg
    $1,040.00
    10 mg
    $1,155.00
    All 5 sizes
  • Parsaclisib hydrochloride
    Cat. No.
    A79807

    Parsaclisib hydrochloride

    Synonyms: INCB050465 hydrochloride; IBI-376 hydrochloride

    Parsaclisib hydrochloride is a selective inhibitor of PI3Kδ, exhibiting an IC50 of 1 nM in the presence of 1 mM ATP. With approximately 20,000-fold selectivity over other PI3K class I isoforms, this orally active compound is valuable for investigating the biochemical pathways involved in B-cell malignancies. It is particularly useful in research focused on relapsed or refractory forms of these cancers.

    1 mg
    $150.00
    5 mg
    $320.00
    All 6 sizes
  • PI3Kα-IN-4
    Cat. No.
    A79808

    PI3Kα-IN-4

    PI3Kα-IN-4 is a selective, potent inhibitor of the phosphoinositide 3-kinase alpha (PI3Kα) with an IC50 value of 1.8 nM. This orally active compound exhibits significant antitumor activity, making it a valuable tool in cancer research. It is primarily used for investigating the role of PI3Kα in oncogenesis and therapeutic resistance.

    5 mg
    $230.00
    10 mg
    $385.00
    All 5 sizes
  • PI3K-IN-36
    Cat. No.
    A79810

    PI3K-IN-36

    PI3K-IN-36 is a potent inhibitor of phosphoinositide 3-kinase (PI3K), a critical enzyme involved in cell signaling pathways. This compound exhibits significant biological activity and is primarily utilized in research focused on follicular lymphoma (FL). Its effectiveness as a PI3K inhibitor makes it a valuable tool for investigating the underlying mechanisms of cancer and testing potential therapeutic strategies.

    5 mg
    $420.00
    10 mg
    $690.00
    All 5 sizes
  • TGX-115
    Cat. No.
    A79811

    TGX-115

    TGX-115 is a selective inhibitor of the p110β and p110δ isoforms of phosphoinositide 3-kinase (PI3-K). It effectively blocks p110β-mediated phosphorylation of Akt in response to lysophosphatidic acid (LPA) in L6 myotubes, and it reduces insulin-stimulated levels of PI(3,4)P2 and PIP3 in 3T3-L1 adipocytes. TGX-115 is a valuable tool for research investigating the mechanisms underlying diabetes mellitus and related metabolic disorders.

    1 mg
    $170.00
    5 mg
    $410.00
    All 7 sizes
  • Roginolisib hemifumarate
    Cat. No.
    A79812

    Roginolisib hemifumarate

    Synonyms: MSC2360844 hemifumarate; IOA-244 hemifumarate

    Roginolisib hemifumarate is a selective inhibitor of the PI3Kδ isoform with an IC50 of 145 nM. This compound demonstrates significant selectivity across a broad panel of 278 additional kinases, making it a valuable tool for the study of signaling pathways involving PI3Kδ. Its potency and specificity facilitate research applications in cancer biology and immune modulation.

    5 mg
    $195.00
    10 mg
    $325.00
    All 5 sizes
  • PI3K-IN-2
    Cat. No.
    A79813

    PI3K-IN-2

    PI3K-IN-2 is a potent and orally bioavailable inhibitor of PI3Kβ and PI3Kδ, exhibiting IC50 values of 7.1 nM and 8.6 nM, respectively. This compound demonstrates excellent selectivity over other isoforms, such as PI3Kσ and PI3Kγ, with IC50 values of 13 nM and 190 nM. Due to its specificity and potency, PI3K-IN-2 is suitable for research applications focusing on cancer, inflammation, and other diseases associated with dysregulated PI3K signaling pathways.

    5 mg
    $470.00
    10 mg
    $805.00
    All 5 sizes
  • PI3K-IN-18 dihydrochloride
    Cat. No.
    A79814

    PI3K-IN-18 dihydrochloride

    PI3K-IN-18 dihydrochloride is a selective inhibitor of the PI3K p110α isoform, derived from a 4-morpholino-2-phenylquinazoline structure. This compound demonstrates significant biological activity in attenuating the PI3K signaling pathway, which plays a crucial role in cell growth, proliferation, and survival. Research applications include cancer biology, where modulation of PI3K activity can provide insights into tumor progression and therapeutic responses.

    1 mg
    $190.00
    5 mg
    $485.00
    All 3 sizes
  • (S)-GSK-F1
    Cat. No.
    A79815

    (S)-GSK-F1

    (S)-GSK-F1 is a potent inhibitor of type III phosphatidylinositol 4-kinase α (PI4KIIIα). It demonstrates inhibitory activity against various kinases, including PI4Kα, PI4Kβ, PI4Kγ, PI3Kα, PI3Kβ, and PI3Kδ, with pIC50 values of 8.3, 6.0, 5.6, 5.6, 5.1, and 5.6, respectively. (S)-GSK-F1 has been shown to effectively inhibit hepatitis C virus (HCV) replication, making it a valuable tool for research in viral infections and signaling pathways. Its moderate pharmacokinetic profiles in rat models support its potential for in vivo studies.

    1 mg
    $55.00
    5 mg
    $115.00
    All 6 sizes
  • Pichromene
    Cat. No.
    A79818

    Pichromene

    Synonyms: S14161

    Pichromene is an anticancer agent that functions as a weak inhibitor of the phosphoinositide 3-kinase (PI3K) pathway. It has demonstrated effectiveness in inhibiting tumor growth in leukemia mouse models, making it a valuable tool for cancer research. This compound may provide insights into therapeutic strategies targeting PI3K-related signaling in malignancies.

    1 mg
    $125.00
    All 1 sizes
  • (S)-PI3K-IN-2
    Cat. No.
    A79819

    (S)-PI3K-IN-2

    (S)-PI3K-IN-2 is a selective inhibitor of phosphoinositide 3-kinase (PI3K) isoforms β and δ, exhibiting IC50 values of 0.198 μM and 0.282 μM, respectively. This compound effectively inhibits phosphorylation of AKT at serine 473 in MDA-MB-468 cancer cells, demonstrating an IC50 of 27 nM. (S)-PI3K-IN-2 is a valuable tool for investigating PI3K signaling pathways and their implications in cancer research.

    5 mg
    $470.00
    10 mg
    $805.00
    All 5 sizes
  • (R)-PI3Kδ-IN-15
    Cat. No.
    A79820

    (R)-PI3Kδ-IN-15

    (R)-PI3Kδ-IN-15 is the R-enantiomer of the selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, PI3Kδ-IN-15. This compound exhibits potent inhibition of PI3Kδ activity, which is critical in regulating immune cell functions and survival. It is primarily utilized in research focused on immune-related disorders and cancer therapies targeting the PI3Kδ pathway.

    5 mg
    $175.00
    10 mg
    $290.00
    All 4 sizes
  • (2S)-SB02024
    Cat. No.
    A79821

    (2S)-SB02024

    (2S)-SB02024 is a selective inhibitor of Vps34, targeting the phosphoinositide 3-kinase pathway. This compound plays a critical role in cellular processes such as autophagy and endocytosis, making it a valuable tool for research in cell biology and cancer studies. Its inhibition of Vps34 provides insights into the regulation of cellular signaling and membrane trafficking.

    1 mg
    $240.00
    5 mg
    $885.00
    All 2 sizes
  • PI3Kδ-IN-15
    Cat. No.
    A79822

    PI3Kδ-IN-15

    PI3Kδ-IN-15 is a highly selective inhibitor of the PI3Kδ isoform, demonstrating an IC50 of 0.5 nM specifically for the p110δ subunit. This compound exhibits over 30-fold greater potency against PI3Kδ compared to other isoforms including PI3Kγ, PI3Kβ, and PI3Kα. PI3Kδ-IN-15 is valuable for research applications targeting immune cell signaling and cancer biology, aiding in the exploration of therapeutic strategies for diseases associated with aberrant PI3Kδ activity.

    5 mg
    $195.00
    10 mg
    $315.00
    All 4 sizes
  • PI3Kδ-IN-9
    Cat. No.
    A79823

    PI3Kδ-IN-9

    PI3Kδ-IN-9 is a selective inhibitor of the phosphoinositide 3-kinase delta (PI3Kδ) with an IC50 value of 3.8 nM. It effectively modulates signaling pathways related to immune responses and inflammation. This compound is utilized in research applications focused on cancer, autoimmune diseases, and other conditions where PI3Kδ plays a critical role in cellular processes.

    5 mg
    $795.00
    All 1 sizes
  • Vps34-IN-3
    Cat. No.
    A79824

    Vps34-IN-3

    Vps34-IN-3 is a selective inhibitor of the VPS34 kinase, a key component of the phosphoinositide 3-kinase (PI3K) signaling pathway. This compound exhibits potent activity, making it suitable for research applications aimed at understanding lipid metabolism, autophagy, and cellular signaling processes. Its oral bioavailability enhances its utility in preclinical studies.

    Out of stock

    All 3 sizes
  • Nemiralisib hydrochloride
    Cat. No.
    A79825

    Nemiralisib hydrochloride

    Synonyms: GSK2269557

    Nemiralisib hydrochloride is a potent and highly selective inhibitor of the phosphoinositide 3-kinase delta (PI3Kδ) pathway, exhibiting a pKi of 9.9. This compound demonstrates significant biological activity in modulating immune responses and is primarily utilized in research related to cancer and autoimmune diseases. Its selective inhibition of PI3Kδ makes it a valuable tool for investigating the roles of this pathway in various cellular processes and therapeutic interventions.

    5 mg
    $90.00
    10 mg
    $150.00
    All 5 sizes
  • MDVN1003
    Cat. No.
    A79826

    MDVN1003

    MDVN1003 is a dual inhibitor of Bruton's tyrosine kinase (BTK) and phosphatidylinositol-3-kinase delta (PI3Kδ). This compound effectively inhibits B cell activation and blocks the phosphorylation of protein kinase B (AKT) as well as extracellular signal-regulated kinases 1 and 2 (ERK 1/2). MDVN1003 is primarily utilized in research related to non-Hodgkin’s lymphoma (NHL), offering insights into the underlying mechanisms of lymphocyte-driven malignancies.

    Out of stock

    All 3 sizes

Items 276-300 of 369

Added to your cart

View Cart Checkout

    Loading...